In the last trading session, 3.65 million Sarepta Therapeutics Inc (NASDAQ:SRPT) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $37.94 changed hands at $1.51 or 4.14% during last session, the market valuation stood at $3.73B. SRPT’s last price was a discount, traded about -356.64% off its 52-week high of $173.25. The share price had its 52-week low at $34.10, which suggests the last value was 10.12% up since then.
Analysts gave the Sarepta Therapeutics Inc (SRPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 1 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended SRPT as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Instantly SRPT was in green as seen at the end of in last trading. With action 4.32%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -68.80%, with the 5-day performance at 4.32% in the green. However, in the 30-day time frame, Sarepta Therapeutics Inc (NASDAQ:SRPT) is -29.47% down.
The consensus price target for the stock as assigned by Wall Street analysts is 156, meaning bulls need an upside of 75.68% from its current market value. According to analyst projections, SRPT’s forecast low is 110 with 202 as the target high. To hit the forecast high, the stock’s price needs a -432.42% plunge from its current level, while the stock would need to soar -189.93% for it to hit the projected low.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
The 2025 estimates are for Sarepta Therapeutics Inc earnings to decrease by -173.69%, but the outlook for the next 5-year period is at 60.51% per year.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.5496% or 9.04 million shares worth $1.43 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF. With 3.15 shares estimated at $119.51 million under it, the former controlled 3.21% of total outstanding shares. On the other hand, iShares Trust-iShares Core S&P Mid-Cap ETF held about 3.17% of the shares, roughly 3.12 shares worth around $118.37 million.
